{"id":817492,"date":"2025-02-25T08:13:31","date_gmt":"2025-02-25T13:13:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/"},"modified":"2025-02-25T08:13:31","modified_gmt":"2025-02-25T13:13:31","slug":"mersana-therapeutics-to-present-at-upcoming-investor-conferences-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/","title":{"rendered":"Mersana Therapeutics to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Feb.  25, 2025  (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>TD Cowen 45th Annual Health Care Conference<\/strong><br \/>\n          <br \/>Format:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Presentation\/fireside chat<br \/>Date\/Time:\u00a0 Tuesday, March 4, 2025, at 1:50 p.m. Eastern Time<\/p>\n<\/li>\n<li>\n          <strong>Leerink Global Healthcare Conference<\/strong><br \/>\n          <br \/>Format: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Fireside chat<br \/>Date\/Time:\u00a0 \u00a0Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time<\/li>\n<\/ul>\n<p>Live webcasts of these events will be available on the Investors &amp; Media section of Mersana\u2019s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events.<\/p>\n<p>\n        <strong>About Mersana Therapeutics<\/strong><br \/>\n        <br \/>Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the \u201cInvestors &amp; Media\u201d section of its website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5PDgTz1Y-5BRRZxZkgVQOwe3ZdgLVgEdJQbAY63AZoqIx0Koaw6m1OnbcHc3QMWtaFSveC0f4DUDb6Qmyew9Kg==\" rel=\"nofollow\" target=\"_blank\">www.mersana.com<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Jason Fredette <br \/>617-498-0020<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s2N75_-YXjlWz1-Egs3tWLx4bB7Uk7mxLcEG63m71HSLj6Zc_fbfWb-u6Ng9JwK9TlWT3hZduZcEcXV9ZMqoUscbjWQ7KbBwjJkQ3AZugiWwGoMI5a-l02lSt9x3QIYO\" rel=\"nofollow\" target=\"_blank\">jason.fredette@mersana.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDQ4MjAwN2MtMDI5Mi00MDQxLTk0ODQtNTIxYzk2MGUyYmY2LTEwOTU2MDI=\/tiny\/Mersana-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events: TD Cowen 45th Annual Health Care Conference Format:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Presentation\/fireside chatDate\/Time:\u00a0 Tuesday, March 4, 2025, at 1:50 p.m. Eastern Time Leerink Global Healthcare Conference Format: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Fireside chatDate\/Time:\u00a0 \u00a0Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time Live webcasts of these events will be available on the Investors &amp; Media section of Mersana\u2019s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events. About Mersana Therapeutics Mersana &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mersana Therapeutics to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-817492","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mersana Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mersana Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events: TD Cowen 45th Annual Health Care Conference Format:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Presentation\/fireside chatDate\/Time:\u00a0 Tuesday, March 4, 2025, at 1:50 p.m. Eastern Time Leerink Global Healthcare Conference Format: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Fireside chatDate\/Time:\u00a0 \u00a0Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time Live webcasts of these events will be available on the Investors &amp; Media section of Mersana\u2019s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events. About Mersana Therapeutics Mersana &hellip; Continue reading &quot;Mersana Therapeutics to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-25T13:13:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mersana Therapeutics to Present at Upcoming Investor Conferences\",\"datePublished\":\"2025-02-25T13:13:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/\"},\"wordCount\":249,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/\",\"name\":\"Mersana Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=\",\"datePublished\":\"2025-02-25T13:13:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mersana Therapeutics to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mersana Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/","og_locale":"en_US","og_type":"article","og_title":"Mersana Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events: TD Cowen 45th Annual Health Care Conference Format:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Presentation\/fireside chatDate\/Time:\u00a0 Tuesday, March 4, 2025, at 1:50 p.m. Eastern Time Leerink Global Healthcare Conference Format: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Fireside chatDate\/Time:\u00a0 \u00a0Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time Live webcasts of these events will be available on the Investors &amp; Media section of Mersana\u2019s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events. About Mersana Therapeutics Mersana &hellip; Continue reading \"Mersana Therapeutics to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-25T13:13:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mersana Therapeutics to Present at Upcoming Investor Conferences","datePublished":"2025-02-25T13:13:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/"},"wordCount":249,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/","name":"Mersana Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=","datePublished":"2025-02-25T13:13:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMSM2NzYxMDA1IzIwODQwMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-present-at-upcoming-investor-conferences-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mersana Therapeutics to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=817492"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817492\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=817492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=817492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=817492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}